1 completed, 1 unknown. 1 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Empagliflozin 10 MG OD: new trials by email Literature Review of Empagliflozin 10 MG OD trials Research Report on Empagliflozin 10 MG OD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment Dapagliflozin 10 mg daily, Empagliflozin 10 MG OD - Diabetes Mellitus, Heart Failure | Not applicable | Completed | Fatima Maqsood | 108 | 2024-07-12 | 2025-04-08 |
| " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD " Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID, Empagliflozin 10 MG OD - Congenital Heart Disease, Heart Failure | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Cardiologia Ignacio Chavez | 160 | 2023-02-06 | 2022-11-02 |
Heart Failure (2) · Diabetes Mellitus (1) · Heart Defects, Congenital (1)
Fatima Maqsood (1) · Instituto Nacional de Cardiologia Ignacio Chavez (1)
Mexico (1) · Pakistan (1)
Carlos Guizar-Sanchez, MD (1) · Edgar Garcia-Cruz, MD (1) · Gian Jimenez-Rodriguez, MD (1) · Montserrat Villalobos-Pedroza, MD (1)
PMID 30520545, PMID 32865377, PMID 33186500, PMID 33447845, PMID 33832352